Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions
Pancreatic Cancer
Interventions
DRUG

ISIS 2503

DRUG

gemcitabine hydrochloride

Trial Locations (16)

55805

CCOP - Duluth, Duluth

55905

Mayo Clinic Cancer Center, Rochester

56303

CentraCare Clinic, Saint Cloud

57709

Rapid City Regional Hospital, Rapid City

58122

CCOP - Merit Care Hospital, Fargo

58501

Medcenter One Health System, Bismarck

61801

CCOP - Carle Cancer Center, Urbana

68131

CCOP - Missouri Valley Cancer Consortium, Omaha

85259-5404

CCOP - Scottsdale Oncology Program, Scottsdale

52403-1206

CCOP - Cedar Rapids Oncology Project, Cedar Rapids

50309-1016

CCOP - Iowa Oncology Research Association, Des Moines

51101-1733

Siouxland Hematology-Oncology, Sioux City

67214-3882

CCOP - Wichita, Wichita

43623-3456

CCOP - Toledo Community Hospital Oncology Program, Toledo

17822-2001

CCOP - Geisinger Clinic and Medical Center, Danville

57105-1080

CCOP - Sioux Community Cancer Consortium, Sioux Falls

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00006467 - Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas | Biotech Hunter | Biotech Hunter